April 17 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO -
* Aurinia completes licensing deal with Merck (NYSE:MRK) Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome
* Aurinia Pharma-signed agreement granting merck animal health worldwide rights to develop, commercialize co's nanomicellar voclosporin ophthalmic solution
* Aurinia Pharma-under deal, co will receive upfront payment, is eligible to receive further payments based on certain development and sales milestones
* Aurinia Pharmaceuticals Inc- under deal, aurinia will receive royalties based on global product sales
* Aurinia Pharma- under deal merck animal health to be responsible for remaining clinical development, commercialization of vos for use in animal health field
* Aurinia pharmaceuticals inc- under deal aurinia retains all human health rights related to vos Source text for Eikon: ID:nBw2FhTka Further company coverage: AUP.TO